Allergan Inc. (NYSE: AGN) is buying Map Pharmaceuticals Inc. (Nasdaq: MAPP) for $958 million.

Mountain View, Calif.-based Map is a biopharmaceutical company focused on developing new neurology medications, including Levadex, an orally inhaled drug that could potentially treat adult migraines. Levadex is currently under review with the U.S. Food and Drug Administration.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.